1-4 of 4
Yong Hao, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Michael R. Savona, MD, James K. McCloskey, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Aref Al-Kali, MD, Amer M. Zeidan, MBBS, MHS, H. Joachim Deeg, MD, Prapti A. Patel, MD, Mitchell Sabloff, MSc,MDFRCPC, Mary-Margaret Keating, MD FRCPC, Kim-Hien Dao, DO, PhD, Nancy Zhu, MD, Nashat Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Hagop M. Kantarjian, MD, Amy E. DeZern, MD, Casey L. O'Connell, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD DPhil, Harshad Amin, MD, Jasleen K. Randhawa, MD, Brian Leber, MD, Yong Hao, MD PhD, Harold N. Keer, MDPhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-133855
Published: 2020
Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Gail J. Roboz, MD, Hartmut Döhner, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw Jedrzejczak, MD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Jean-Pierre Issa, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2591.
https://doi.org/10.1182/blood-2019-127253
Published: 2019
Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Guillermo Garcia-Manero, MD, James McCloskey, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Amer M. Zeidan, MBBS, MHS, Aref Al-Kali, MD, Kim-Hien Dao, DO, PhD, H. Joachim Deeg, MD, Prapti A. Patel, MD, Mitchell Sabloff, MSc,MDFRCPC, Mary-Margaret Keating, MD, Nancy Zhu, MD, Nashat Y. Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Aditi Shastri, MD, Amy E. DeZern, MD, Casey L. O'Connell, MD, Gail J. Roboz, MD, Aram Oganesian, PhD, Yong Hao, MD PhD, Harold N. Keer, MD PhD, Mohammad Azab, MD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 846.
https://doi.org/10.1182/blood-2019-122980
Published: 2019
Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Jean-Pierre Issa, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Pierre Fenaux, MD PhD, Gail J. Roboz, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4235.
https://doi.org/10.1182/blood-2019-129614
Published: 2019